$RPM

RPM International (NYSE:RPM) Given New $121.00 Price Target at Morgan Stanley

Morgan Stanley has raised its price target for RPM International (NYSE:RPM) to $121.00 from $118.00, maintaining an "equal weight" rating and suggesting a 7.27% upside. This adjustment comes after RPM beat Q3 earnings expectations with $0.57 EPS and $1.61 billion in revenue, driving a recent share rally. The company currently has a "Moderate Buy" consensus rating from analysts, with a $125.75 average price target.

Original reporting
MarketBeat · MarketBeat
Published Apr 9, 2026, 6:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 9, 2026, 6:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RPM International (NYSE:RPM) Given New $121.00 Price Target at Morgan Stanley — source image
Decision brief

The 30-second read

$RPMBullishMed
01

Why it matters

The upgrade suggests confidence in RPM's growth prospects, potentially leading to increased investor interest.

02

Market read

The news is relevant for investors and traders focusing on the industrial and manufacturing sectors, especially those with exposure to RPM.

03

What to watch

Potential macroeconomic headwinds or sector-specific challenges could limit upside despite positive earnings.

Timing: Immediate, as the news is recent and may influence short-term trading decisions.

Background

RPM International reported better-than-expected Q3 earnings, prompting analyst upgrades.

Company-level read

Ticker impact

$RPMBullishHigh confidence
Context

The news pertains directly to RPM International, a key company in the manufacturing and building materials sector.

Expected impact

Moderate upward movement in the near term, with potential for price appreciation towards the new target.

Evidence & confidence

The earnings beat and analyst upgrade provide solid fundamentals and positive sentiment, supporting a bullish outlook.

Market effects

The upgrade may boost investor confidence in the industrial and manufacturing sectors.

Primarily affects US markets, given RPM's NYSE listing.

Limited, as RPM is a regional leader with a focus on North America.

Counterpoint

The price target increase may already be priced in, and the stock could experience a short-term pullback after the rally.

Key entities

  • Morgan Stanley

    The investment bank that raised RPM's price target.

  • RPM International

    The subject of the analyst upgrade and earnings report.

Related articles

$RPMMed

RPM (RPM) Q4 2026 Earnings Call Transcript

RPM held its Q4 2026 earnings call, reporting consolidated sales up 7.2% to a record and record adjusted EBIT and adjusted EPS, driven by engineered solutions, pricing to offset inflation, and M&A. Management said SG&A optimization actions are on track for $75 million in fiscal 2027 savings and expects raw-material inflation of 5% to 6% in Q1 2027 and 6% to 8% in Q2.

$RPMMed

RPM INTERNATIONAL INC/DE/ (RPM): Results of Operations and Financial Condition

RPM INTERNATIONAL INC/DE/ (RPM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d141573dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 RPM Reports Record Fiscal 2026 Fourth-Quarter and Full-Year Results • Record fourth-quarter sales of $2.23 billion increased 7.2% compared to the prior year • Fourth-quarter net income of $221.2 million, diluted EPS of $1.7

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.